Antiplatelet therapy in patients undergoing coronary stent implantation: Italian Society of Interventional Cardiology consensus document

Journal of Cardiovascular Medicine

Volumn 8, Issue 10, 2007, Pages 782-791

  Guagliumi, Giulio ^a   Musumeci, Giuseppe ^a   Rossini, Roberta ^a   Bolognese, Leonardo ^b   Giordano, Arturo ^b   Marzocchi, Antonio ^a   Ramondo, Angelo ^b   Sangiorgi, Giuseppe ^b   Tamburino, Corrado ^b   Tomai, Fabrizio ^b   De Servi, Stefano ^b  

^a OSPEDALI RIUNITI   (Italy)

^b Consiglio Direttivo Della Societa' Italiana di Cardiologia Invasiva ^*  (Italy)

Author keywords

Antiplatelet agents; Coronary thrombosis; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; LOW MOLECULAR WEIGHT HEPARIN; PRASUGREL; RAPAMYCIN; THIENOPYRIDINE; TICLOPIDINE; UNCLASSIFIED DRUG; WARFARIN;

ADD ON THERAPY; ANTICOAGULANT THERAPY; BLEEDING; BLOOD DYSCRASIA; CLINICAL TRIAL; CONSENSUS; CONSENSUS DEVELOPMENT; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DIARRHEA; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEALING; HEART DEATH; HEART INFARCTION; HUMAN; IMPLANTATION; INCIDENCE; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ITALY; LOADING DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; REPEATED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

CORONARY THROMBOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; PLATELET AGGREGATION INHIBITORS; PROSTHESES AND IMPLANTS;

EID: 34748866016     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3282785250     Document Type: Review

References (70)

1. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489-495.
2. Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol 1999; 34:1498-1506.
3. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996; 93:215-222.
4. Schömig A, Neumann FJ, Kastrati A, Schühlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084-1089.
5. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-1671.
6. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, et al. Randomized multicentre comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998; 98:1597-1603.
7. Urban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicentre aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98:2126-2132.
8. Morice M-C, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a Sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-1780.
9. Schampaert E, Moses JW, Schofer J, Schlüter M, Gershlick AH, Cohen EA, et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 2006; 98:36-41.
10. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003; 108:788-794.
11. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al., REALITY Trial Investigators. Sirolimus vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295:895-904.
12. Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, et al. The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005; 45:1135-1141.
13. Wijns W. ENDEAVOR II trial results. American College of Cardiology 2005 Scientific Sessions. Orlando, Florida: American College of Cardiology; 6-9 March 2005.
14. van Domburg RT, Lemos PA, Takkenberg JJ, Liu TKK, van Herwerden LA, Arampatzis CA, et al. The impact of the introduction of drug-eluting stents on the clinical practice of surgical and percutaneous treatment of coronary artery disease. Eur Heart J 2005; 26:675-681.
15. Wenaweser P, Rey C, Eberli FR, Togni M, Tüller D, Locher S, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005; 26:1180-1187.
16. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans. Delayed healing and late thrombotic. J Am Coll Cardiol 2006; 48:193-202.
17. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006; 47:2108-2111.
18. Moreno R, Fernandez C, Hernandez R, Alfonso F, Angiolillo DJ, Sabaté M, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Card 2005; 45:954-959.
19. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364:583-591.
20. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:989-997.
21. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparino sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:1030-1039.
22. Mauri L, Hsieh W, Massaro JM, Ho KKL, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trias of drug-eluting stents. N Engl J Med 2007; 356:1020-1029.
23. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356:998-1008.
24. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, et al., on behalf of the International e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113:1434-1441.
25. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al., for the BASKET-LATE investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol 2006; 48:2584-2591.
26. Camenzind E. Safety of drug-eluting stents: Insights from meta analysis. Available at: http://www.escardio.org/knowledge/congresses/congressreports/ hotlinesandctus/707009_Camenzind.htm. [Accessed 13 December 2006]
27. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled clinical trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta analysis. Eur Heart J 2006; 27:2784-2814.
28. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L, for the SCAAR study group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356:1009-1019.
29. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Circulation 2007; 115:1433-1439.
30. Spaulding C. Trial to assess the use of the cypher stent in acute myocardial infarction treated with balloon angioplasty (TYPHOON). American College of Cardiology 2006 Scientific Sessions. Atlanta, GA: American College of Cardiology; 12 March 2006.
31. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, Rumsfeld JS, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113:2803-2809.
32. Berger PB, Bell MR, Hasdai D, Grill DE, Melby S, Holmes DR Jr. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement. Circulation 1999; 99:248-253.
33. Herbert JM, Frechel D, Vallee E, Kieffer D, Gouy D, Berger Y, et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993; 11:180-198.
34. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102:624-629.
35. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation 2001; 104:539-543.
36. Müller C, Büttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101:590-593.
37. Moussa I, Oetgen M, Roubin G, Colombo A, Wang X, Iyer S, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99:2364-2366.
38. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39:9-14.
39. Casella G, Ottani F, Paversi PC, Sangiorgio P, Rubboli A, Galvani M, et al. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis. Ital Heart J 2003; 4:677-684.
40. Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004; 25:166-181.
41. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. JAMA 1999; 281:806-810.
42. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med 1999; 159:2524-2528.
43. Sarode R, Gottschall JL, Aster RH, McFarland JG. Thrombotic thrombocytopenic purpura: early and late responders. Am J Hematol 1997; 54:102-107.
44. Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339:1585-1594.
45. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339:1578-1584.
46. Bennet CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342:1773-1777.
47. Steinhubl SR, Berger PB, Brennan DM, Topol EJ, CREDO Investigators. Optimal timing for the initiation of pretreatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939-943.
48. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111:2099-2106.
49. Berger PB, Steinhubl S. Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation 2002; 106:2284-2287.
50. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108:1682-1687.
51. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004; 110:1202-1208.
52. Lecompte T, Hardy JF. Antiplatelet agents and perioperative bleeding. Can J Anaesth 2006; 53 (suppl 6):S103-S112.
53. Serebruany VL, Midei MG, Meilman H. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non compliance in patient enrolled in the JUMBO Trial International. J Clin Practice 2006; 60:863.
54. Eagle K, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, et al. ACC/AHA Guideline Update for Perioperative Cardiovascular Evaluation for Noncardiac Surgery - Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Circulation 2002; 105:1257-1267.
55. Batchelor WB, Mahaffey KW, Berger PB, Deutsch E, Meier S, Hasselblad V, et al., ATLAST Trial Investigators. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. J Am Coll Cardiol 2001; 38:1608-1613.
56. Orford JL, Fasseas P, Melby S, Burger K, Steinhubl SR, Holmes DR, Berger PB. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004; 147:463-467.
57. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109:3171-3175.
58. Steinhubl SR, Berger PB, Mann JT, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411-2420.
59. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908-2913.
60. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89:783-787.
61. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59:295-302.
62. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000; 129:1439- 1446.
63. Brandt JT, Payne CD, Weerakkody G, Behounek BD, Naganuma H, Jakubowski JA, et al. Superior responder rate for inhibition of platelet aggregation with a 60mg loading dose of prasugrel (CS-747, LY640315) compared with a 300mg loading dose of clopidogrel. J Am Coll Cardiol 2005; 45 (Suppl):87A.
64. Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, et al., for the JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention. Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial. Circulation 2005; 111:3366-3373.
65. Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, et al. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for Percutaneous Coronary Interventions. Eur Heart J 2005; 26:804-847.
66. Smith SC Jr, Feldman TE, Hirshfeld JW, Jacobs AK, Kern MJ, King SB III, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47:216-235.
67. Cannon CP. CAPRIE Investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial). Am J Cardiol 2002; 90:760-762.
68. Shuchman M. Debating the risks for drug-eluting stents. New Engl J Med 2007; 356:325-328.
69. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115:813-818.
70. Hodgson JM, Stone GW, Michael Lincoff A, Klein L, Walpole H, Bottner R, et al. Late stent thrombosis: considerations and practical advice for the use of drug-eluting stents: A report from the Society for Cardiovascular Angiography and Interventions drug-eluting stent task force. Catheter Cardiovasc Interv 2007; 69:327-333.